Artiva Biotherapeutics, Inc. (ARTV) Misses Q2 EPS by 63c
Tweet
Share
E-mailGet Alerts ARTV Hot Sheet
Join SI Premium – FREE
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) reported Q2 EPS of ($0.63), $0.63 worse than the analyst estimate of $0.00.
For earnings history and earnings-related data on Artiva Biotherapeutics, Inc. (ARTV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Downgrades Monopar Therapeutics (MNPR) to Neutral
- Morgan Stanley Upgrades Oil India Ltd. (OINL:IN) to Equalweight
- Wells Fargo Upgrades SM Energy (SM) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
